Companies Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (XENE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Xenon Pharmaceuticals Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 18 peer CEOs
CEO pay, last three years
- $10,117,829FY2023
- $9,795,347FY2024
- $9,221,712FY2025
CEO total pay was $9,221,712 in fiscal 2025, down from $9,795,347 in fiscal 2024.
FY2025: salary $786,000 · bonus $0 · stock awards $1,774,000 · option awards $6,065,255
Executives and directors
Darren Cline · CCOIan Mortimer · CEOAndrea DiFabio · General CounselChristopher Kenney · Chief Medical OfficerSherry Aulin · CFOThomas Kelly · CFODawn Svoronos · Chair of the BoardElizabeth Garofalo · Independent DirectorGary Patou · Independent DirectorGillian Cannon · Independent DirectorJustin Gover · Independent DirectorPatrick Machado · Independent DirectorSteven Gannon · Independent Director
Frequently asked questions
Who was the highest-paid executive at Xenon Pharmaceuticals Inc. in fiscal 2025?
As disclosed, Ian Mortimer (President and Chief Executive Officer) was the highest-paid executive at Xenon Pharmaceuticals Inc. in fiscal 2025, with total compensation of $9,221,712.
How does Xenon Pharmaceuticals Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Ian Mortimer's total compensation ranked at the 50th percentile of Xenon Pharmaceuticals Inc.'s disclosed peer group.
What is Xenon Pharmaceuticals Inc.'s CEO-to-median employee pay ratio?
As disclosed, Xenon Pharmaceuticals Inc.'s CEO-to-median employee pay ratio was 37:1.
How did shareholders vote on Xenon Pharmaceuticals Inc.'s executive compensation?
As disclosed, 94.51% of shareholders supported Xenon Pharmaceuticals Inc.'s executive compensation in the latest say-on-pay vote.
How much does Xenon Pharmaceuticals Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Xenon Pharmaceuticals Inc. reported total board compensation of $1,029,197 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ian Mortimer | $786,000 | $0 | $1,774,000 | $6,065,255 | $550,200 | $0 | $46,257 | $9,221,712 |
| President and Chief Executive Officer | ||||||||
| Thomas Kelly | 114,545 | 0 | 1,257,000 | 5,809,602 | 51,545 | 0 | 5,972 | 7,238,664 |
| Chief Financial Officer | ||||||||
| Darren Cline | 279,659 | 0 | 0 | 3,628,123 | 125,847 | 0 | 14,585 | 4,048,214 |
| Chief Commercial Officer | ||||||||
| Christopher Kenney | 565,000 | 0 | 532,200 | 1,764,438 | 254,250 | 0 | 29,402 | 3,145,290 |
| Chief Medical Officer | ||||||||
| Andrea DiFabio | 510,000 | 0 | 532,200 | 1,764,438 | 229,500 | 0 | 26,652 | 3,062,790 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Sherry Aulin | 330,441 | 1,539 | 0 | 0 | 0 | 0 | 24,473 | 356,453 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ian Mortimer | $9,221,712 | $9,795,347 | $10,117,829 | ↓ −573,635 |
| Thomas Kelly | 7,238,664 | — | — | — |
| Darren Cline | 4,048,214 | — | — | — |
| Christopher Kenney | 3,145,290 | 4,196,940 | 3,578,066 | ↓ −1,051,650 |
| Andrea DiFabio | 3,062,790 | 4,104,490 | 1,721,162 | ↓ −1,041,700 |
| Sherry Aulin | 356,453 | 4,164,888 | 3,523,045 | ↓ −3,808,435 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The primary objectives of the executive compensation program are to attract, retain, and motivate experienced executives, align compensation with corporate strategies and business goals, and link a portion of annual and long-term incentive compensation to the achievement of key strategic and operational objectives to align executive interests with shareholders.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Kelly | OPTION | 2025-10-15 | — | — | 225,000 | — | $5,809,602 |
| Thomas Kelly | RSU | 2025-10-15 | — | — | 30,000 | — | 1,257,000 |
| Darren Cline | OPTION | 2025-06-23 | — | — | 185,800 | — | 3,628,123 |
| Andrea DiFabio | OPTION | 2025-03-12 | — | — | 80,000 | — | 1,764,438 |
| Christopher Kenney | OPTION | 2025-03-12 | — | — | 80,000 | — | 1,764,438 |
| Ian Mortimer | OPTION | 2025-03-12 | — | — | 275,000 | — | 6,065,255 |
| Andrea DiFabio | RSU | 2025-03-12 | — | — | 15,000 | — | 532,200 |
| Christopher Kenney | RSU | 2025-03-12 | — | — | 15,000 | — | 532,200 |
| Ian Mortimer | RSU | 2025-03-12 | — | — | 50,000 | — | 1,774,000 |
| Darren Cline | PSU | 2025-06-23 | — | 6,200 | — | — | — |
| Andrea DiFabio | PSU | 2025-03-12 | — | 6,200 | — | — | — |
| Christopher Kenney | PSU | 2025-03-12 | — | 6,200 | — | — | — |
| Ian Mortimer | PSU | 2025-03-12 | — | 21,650 | — | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Kelly | $1,257,000 | $0 | $5,809,602 | 0.0% |
| Darren Cline | 0 | 0 | 3,628,123 | 0.0% |
| Andrea DiFabio | 532,200 | 0 | 1,764,438 | 0.0% |
| Christopher Kenney | 532,200 | 0 | 1,764,438 | 0.0% |
| Ian Mortimer | 1,774,000 | 0 | 6,065,255 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Darren Cline | PSU | 6,200 | — | $277,884 |
| Andrea DiFabio | PSU | 6,200 | — | 277,884 |
| Christopher Kenney | PSU | 6,200 | — | 277,884 |
| Andrea DiFabio | Option | 11,250 | 34.18 | — |
| Andrea DiFabio | PSU | 15,000 | — | 672,300 |
| Christopher Kenney | PSU | 15,000 | — | 672,300 |
| Ian Mortimer | PSU | 21,650 | — | 970,353 |
| Andrea DiFabio | Option | 28,125 | 34.77 | — |
| Thomas Kelly | PSU | 30,000 | — | 1,344,600 |
| Christopher Kenney | Option | 30,000 | 34.18 | — |
| Ian Mortimer | PSU | 40,000 | — | 1,792,800 |
| Ian Mortimer | PSU | 50,000 | — | 2,241,000 |
| Andrea DiFabio | Option | 50,000 | 44.37 | — |
| Christopher Kenney | Option | 50,000 | 44.37 | — |
| Andrea DiFabio | Option | 80,000 | 35.48 | — |
| Christopher Kenney | Option | 80,000 | 35.48 | — |
| Ian Mortimer | Option | 95,000 | 34.18 | — |
| Ian Mortimer | Option | 125,000 | 44.37 | — |
| Darren Cline | Option | 185,800 | 31.49 | — |
| Thomas Kelly | Option | 225,000 | 41.9 | — |
| Ian Mortimer | Option | 275,000 | 35.48 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dawn SvoronosIndependent · Board Chair · Lead Independent Director · Nominating and Corporate Governance (Chair) | $92,890 | $81,281 | $324,752 | $0 | $0 | $498,923 |
| Justin GoverIndependent · Compensation (Chair) · Audit | 72,890 | 81,281 | 324,752 | 0 | 0 | 478,923 |
| Steven GannonIndependent · Audit (Chair) | 67,890 | 81,281 | 324,752 | 0 | 0 | 473,923 |
| Patrick MachadoIndependent · Compensation · Nominating and Corporate Governance · Audit | 65,390 | 81,281 | 324,752 | 0 | 0 | 471,423 |
| Gary PatouIndependent · Compensation | 55,390 | 81,281 | 324,752 | 0 | 0 | 461,423 |
| Elizabeth GarofaloIndependent · Audit · Nominating and Corporate Governance | 52,890 | 81,281 | 324,752 | 0 | 0 | 458,923 |
| Gillian CannonIndependent · Audit | 52,890 | 81,281 | 324,752 | 0 | 0 | 458,923 |
| Ian MortimerEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $440,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $460,230 |
| Equity awards (grant-date value) | $568,967 |
| All other compensation | $0 |
| Total cost of the board | $1,029,197 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Xenon Pharmaceuticals as a peer
Companies that benchmark against XENE
4 companies name XENE as a compensation peer
- AbCellera Biologics Inc.ABCLFY2025
- Biohaven Ltd.BHVNFY2025
- Dyne Therapeutics, Inc.DYNFY2025
- Immunovant, Inc.IMVTFY2026
- Verona Pharma plcVRNAFY2024
Each company listed discloses XENE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named XENE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CYTK CytokineticsMDGL Madrigal Pharmaceuticals, Inc.IOVA Iovance Biotherapeutics, Inc.ARWR Arrowhead Pharmaceuticals, Inc.SWTX SpringWorks Therapeutics, Inc.APLS Apellis Pharmaceuticals, Inc.IBRX ImmunityBio, Inc.NMRA Neumora Therapeutics, Inc.AGIO Agios Pharmaceuticals Inc.ARVN Arvinas, Inc.AUPH Aurinia Pharmaceuticals Inc.BHVN Biohaven Ltd.AXSM Axsome Therapeutics, Inc.DAWN Day One Biopharmaceuticals, Inc.IMVT Immunovant, Inc.DNLI Denali Therapeutics Inc.ITCI Intra-Cellular Therapies, Inc.PRTA Prothena Corporation plc
Peer reciprocity
The companies Xenon Pharmaceuticals Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant, Inc. | 2026 | Eric Venker | $636,618 | $0 | $19,010,639 | $0 | $20,158,767 |
| 2 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | Biohaven Ltd. | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 5 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 6 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 7 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 9 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 10 | Xenon Pharmaceuticals Inc. | 2025 | Ian Mortimer | 786,000 | 1,774,000 | 6,065,255 | 550,200 | 9,221,712 |
| 11 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 12 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 13 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 14 | Prothena Corporation plc | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 15 | Aurinia Pharmaceuticals Inc. | 2025 | Peter Greenleaf | 822,877 | 1,965,321 | 2,193,189 | 864,021 | 5,858,590 |
| 16 | Agios Pharmaceuticals Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 17 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 18 | Neumora Therapeutics, Inc. | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 19 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | 100% | not disclosed | No | Aon |
| Agios Pharmaceuticals Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Aurinia Pharmaceuticals Inc. | not disclosed | not disclosed | not disclosed | WTW |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biohaven Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| ImmunityBio, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Neumora Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Prothena Corporation plc | 100% | not disclosed | not disclosed | Pay Governance LLC |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 82,156,320 | 4,769,025 | 67,157 | 94.51% | Passed |
| 2025 | 2025-06-04 | 67,252,200 | 2,125,675 | 459,935 | 96.94% | Passed |
| 2024 | 2024-06-04 | 63,950,064 | 1,979,402 | 13,742 | 97% | Passed |
| 2023 | 2023-06-01 | 44,167,661 | 6,700,364 | 3,320 | 86.83% | Passed |
| 2022 | 2022-06-01 | 41,145,105 | 606,074 | 4,266 | 98.55% | Passed |
| 2021 | 2021-06-03 | 30,551,667 | 85,511 | 23,575 | 99.72% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-02 | 94.51%a |
| 2025 | 2025-06-04 | 96.94%b |
| 2024 | 2024-06-04 | 97%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 37 : 1 |
|---|---|
| CEO total compensation | $9,221,712 |
| Median employee compensation | $246,438 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Steven Gannon | Director | 2026-05-12 | D | 3,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-05-12 | A | 3,500 | 7 | 25,830 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | D | 1,416 | 53 | 75,629 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | D | 1,416 | 53 | 75,629 | Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-03 | — | 11,151 | — | — | 7 insiders, 7 accrual rows | ||
| Steven Gannon | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-05 | D | 1,190 | 53 | 63,237 | Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-05 | D | 1,322 | 53 | 70,251 | Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-08-11 | D | 10,000 | 64 | 640,550 | Common | Form 4 ↗ |
| Christopher Kenney | Chief Medical Officer | 2026-08-28 | D | 700 | 61 | 42,684 | Common | Form 4 ↗ |
| Christopher Kenney | Chief Medical Officer | 2026-08-28 | D | 6,368 | 60 | 383,145 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-09-01 | D | 5,144 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-09-01 | A | 5,144 | 8 | 41,924 | Common | Form 4 ↗ |
| Ian Mortimer | Director | 2026-09-30 | A | 30,000 | 37 | 1,121,400 | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-09-30 | A | 15,000 | 37 | 559,740 | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-10-15 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-10-15 | A | 7,500 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 43 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Steven Gannon | Director | 2026-05-12 | D | 3,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-05-12 | A | 3,500 | 7 | 25,830 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | D | 1,416 | 53 | 75,629 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | D | 1,416 | 53 | 75,629 | Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-01 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-01 | A | 2,645 | — | — | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Justin Gover | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Machado | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-03 | A | 1,593 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-03 | A | 10,507 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gillian Cannon | Director | 2026-06-05 | D | 1,190 | 53 | 63,237 | Common | Form 4 ↗ |
| Gary Patou | Director | 2026-06-05 | D | 1,322 | 53 | 70,251 | Common | Form 4 ↗ |
| Steven Gannon | Director | 2026-08-11 | D | 10,000 | 64 | 640,550 | Common | Form 4 ↗ |
| Christopher Kenney | Chief Medical Officer | 2026-08-28 | D | 700 | 61 | 42,684 | Common | Form 4 ↗ |
| Christopher Kenney | Chief Medical Officer | 2026-08-28 | D | 6,368 | 60 | 383,145 | Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-09-01 | D | 5,144 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dawn Svoronos | Director | 2026-09-01 | A | 5,144 | 8 | 41,924 | Common | Form 4 ↗ |
| Ian Mortimer | Director | 2026-09-30 | A | 30,000 | 37 | 1,121,400 | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-09-30 | A | 15,000 | 37 | 559,740 | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-10-15 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2026-10-15 | A | 7,500 | — | — | Common | Form 4 ↗ |
Sources (98 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ian Mortimer. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · page 41. As printed: 9,221,712. View filing ↗
- Section 01, Thomas Kelly. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 7,238,664. View filing ↗
- Section 01, Darren Cline. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 4,048,214. View filing ↗
- Section 01, Christopher Kenney. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 3,145,290. View filing ↗
- Section 01, Andrea DiFabio. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 3,062,790. View filing ↗
- Section 01, Sherry Aulin. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 356,453. View filing ↗
- Section 03, Thomas Kelly OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Kelly RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Darren Cline OPTION. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrea DiFabio OPTION. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Kenney OPTION. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ian Mortimer OPTION. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrea DiFabio RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Kenney RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ian Mortimer RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Darren Cline PSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrea DiFabio PSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Kenney PSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ian Mortimer PSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: 37 : 1. View filing ↗
- Section 08, Dawn Svoronos. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 498,923. View filing ↗
- Section 08, Justin Gover. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 478,923. View filing ↗
- Section 08, Steven Gannon. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 473,923. View filing ↗
- Section 08, Patrick Machado. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 471,423. View filing ↗
- Section 08, Gary Patou. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 461,423. View filing ↗
- Section 08, Elizabeth Garofalo. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 458,923. View filing ↗
- Section 08, Gillian Cannon. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 458,923. View filing ↗
- Section 08, Ian Mortimer. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Steven Gannon 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gillian Cannon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Gover 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Gover 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Patou 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Patou 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gillian Cannon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Gover 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Gover 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Machado 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gillian Cannon 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gillian Cannon 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Patou 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Patou 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gillian Cannon 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Patou 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Gannon 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Kenney 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Kenney 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Svoronos 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Mortimer 2026-09-30. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2026-09-30. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-03. Item 5.07 · say-on-pay result. As reported: 94.51% (votes for as printed: 82,156,320.53). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 96.94% (votes for as printed: 67,252,200). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-05. Item 5.07 · say-on-pay result. As reported: 97% (votes for as printed: 63,950,064). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 460,230 + equity 568,967 + all other 0 = 1,029,197, summed across the director compensation table rows.
- Immunovant, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- Biohaven Ltd., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven Ltd.'s own proxy. As printed: 13,500,438. View filing ↗
- ImmunityBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
- Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
- Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
- Xenon Pharmaceuticals Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Xenon Pharmaceuticals Inc.'s own proxy. As printed: 9,221,712. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Day One Biopharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Prothena Corporation plc, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Prothena Corporation plc's own proxy. As printed: 5,896,045. View filing ↗
- Aurinia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Aurinia Pharmaceuticals Inc.'s own proxy. As printed: 5,858,590. View filing ↗
- Agios Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Neumora Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Neumora Therapeutics, Inc.'s own proxy. As printed: 4,562,461. View filing ↗
- Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
- Section 10a, Biohaven Ltd. reciprocity. DEF 14A. Biohaven Ltd. names Xenon Pharmaceuticals Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Immunovant, Inc. reciprocity. DEF 14A. Immunovant, Inc. names Xenon Pharmaceuticals Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗